Nattokinase Dosage Guide

Most nattokinase supplements are sold at 2,000 FU per capsule — but clinical research now spans doses from 2,000 FU all the way to 10,800 FU per day, and the right amount for you depends on what you are trying to accomplish.

Nattokinase is a fibrinolytic enzyme derived from natto, a traditional Japanese fermented soybean food. It works by breaking down fibrin — the protein that forms the structural mesh of blood clots — and by inhibiting plasminogen activator inhibitor-1 (PAI-1), which helps your body's own clot-clearing system work more effectively. According to a 2015 study published in Scientific Reports, fibrinolytic activity begins within 2 hours of oral ingestion and persists for up to 8 hours after a single dose. For a broader overview of what this enzyme is and how it was discovered, see our complete guide to nattokinase.

This guide covers what the evidence says about dosing — from the well-studied 2,000 FU standard to the higher-dose protocols used in cardiovascular research — plus timing, delivery format, and the safety considerations everyone should understand before starting.

Table of Contents

1. What FU Means and Why It Matters More Than Milligrams
2. The Standard 2,000 FU Dose: What the Research Shows
3. Higher Doses: When 2,000 FU May Not Be Enough
4. Timing and Fasted State: How to Take Nattokinase Correctly
5. Delivery Format: Why Capsule Type Affects Results
6. Safety and Who Should Avoid Nattokinase
7. BioAbsorb Nattokinase Enzyme — Dosage You Can Count On
8. Frequently Asked Questions
9. Conclusion
10. Research References

1. What FU Means and Why It Matters More Than Milligrams

Nattokinase supplements list two numbers on the label: milligrams (mg) and fibrinolytic units (FU). Most shoppers focus on the milligrams, but the FU figure is the more important measurement. Milligrams tell you how much enzyme powder is in the capsule; FU measures the enzyme's actual biological activity — its ability to break down fibrin clots. A 100 mg capsule of low-potency nattokinase can have far less clot-dissolving power than a 100 mg capsule of high-potency extract, even though both show the same milligram count on the label. Understanding how nattokinase works at a biochemical level makes clear why this distinction matters so much in practice.

The fibrinolytic unit scale was standardized by the Japan Bio Science Laboratory and is widely used in clinical research. According to published dosing analyses, 2,000 FU is roughly equivalent to 100 mg of standard-potency nattokinase — which is why clinical trials typically use doses of 100–200 mg and simultaneously report 2,000–4,000 FU. Both figures describe the same capsule, but FU is the number that tells you whether the enzyme is actually potent enough to do its job.

When comparing products, always cross-reference both figures. A supplement listing only milligrams without FU activity is omitting the most clinically relevant measurement. The same principle applies when reading study results: dose comparisons across studies are only meaningful when both express dose in FU.

2. The Standard 2,000 FU Dose: What the Research Shows

The most studied nattokinase dose is 2,000 FU per day — one standard capsule. This is the dose used in the pivotal randomized, double-blind, placebo-controlled trial published in Hypertension Research (2008), which enrolled 86 participants with systolic blood pressure of 130–159 mmHg. After 8 weeks of daily 2,000 FU supplementation, participants experienced a mean 5.55 mmHg reduction in systolic blood pressure compared to placebo. Diastolic blood pressure also declined significantly.

A 2023 systematic review and meta-analysis published in Reviews in Cardiovascular Medicine pooled data from 6 RCTs involving 546 participants and confirmed that nattokinase supplementation significantly reduced systolic blood pressure (mean difference: −3.45 mmHg, 95% CI: −4.37 to −2.18, p < 0.00001) and diastolic blood pressure. The same meta-analysis noted that lower total daily doses of nattokinase had a measurable negative effect on total cholesterol and HDL levels, suggesting the dose-response relationship may vary by outcome. Importantly, the 2015 Scientific Reports single-dose study demonstrated that even one 2,000 FU capsule produced measurable fibrinolytic effects within hours: D-dimer levels rose approximately 44% at 6 hours and 38% at 8 hours post-dose — the first direct confirmation that oral nattokinase is absorbed intact and retains activity in the bloodstream.

The 2,000 FU per day dose has a strong safety profile in published trials. Studies lasting up to 8 weeks at this level have reported no serious adverse events in healthy participants and in those with mild-to-moderate cardiovascular risk factors. For most adults beginning nattokinase for general cardiovascular maintenance, 2,000 FU once daily is the evidence-supported starting point recommended by integrative medicine guidelines from the University of Wisconsin.

3. Higher Doses: When 2,000 FU May Not Be Enough

For specific cardiovascular applications — particularly atherosclerosis management, thrombosis risk reduction, or antithrombotic support — research points to higher doses. A published dosing review summarized in a 2025 review in Nutrients notes that the effective daily dose range is 2,000–4,000 FU for general cardiovascular maintenance, with 4,000 FU per day (split into two doses) used when antithrombotic or thrombolytic effects are specifically needed. Short-term studies have found no serious side effects at doses up to 10,000 FU per day, though long-term high-dose data remain limited.

The most striking high-dose evidence comes from a large clinical study of 1,062 participants published in Frontiers in Cardiovascular Medicine (2022), in which 10,800 FU per day for 12 months produced improvement rates of 66.5 to 95.4% for carotid artery intima-media thickness and plaque size — the authors explicitly challenged the widely cited 2,000 FU recommendation. However, this study had a non-randomized, retrospective design without a placebo control group, and the authors noted that co-administration of vitamin K2, aspirin, and some lifestyle changes may have contributed to the outcomes. This remains the only large human study at 10,800 FU, and its observational limitations mean it cannot serve as standalone evidence for high-dose dosing in the general population.

A practical framework for dose selection: 2,000 FU once daily for general maintenance; 4,000 FU split across two daily doses (morning and evening) for active blood pressure support or elevated cardiovascular risk; and higher doses only under physician supervision, given that consistent long-term safety data above 4,000 FU is still accumulating. The emerging clinical picture suggests nattokinase follows a dose-response curve for fibrinolytic outcomes, but the inflection points between dose tiers are not yet precisely defined by randomized trial data.

4. Timing and Fasted State: How to Take Nattokinase Correctly

Timing matters for nattokinase because of its mechanism as an enzyme. Nattokinase is a protein — and when taken with food, stomach proteases designed to digest dietary protein will begin breaking it down before it reaches the small intestine. Research on gastric enzyme dynamics shows that an empty stomach has significantly lower acid and protease levels, allowing the capsule to transit the stomach faster and with less enzymatic degradation. The general guidance across clinical studies and integrative medicine practitioners is to take nattokinase at least 30–60 minutes before eating, or 2 hours after a meal.

As for the time of day, no clinical evidence currently establishes morning as superior to evening — or vice versa. Fibrinolytic activity from a 2,000 FU dose peaks within 2–4 hours and measurably persists for up to 8 hours post-ingestion, based on the Scientific Reports single-dose study. Some practitioners suggest evening dosing to align enzyme activity with the overnight period, when coagulation activity and cardiovascular event risk are slightly elevated in some individuals. Others prefer morning dosing for consistency. For daily single-dose protocols, consistency matters more than the specific hour. For split 4,000 FU protocols, taking one capsule in the morning and one in the evening maintains more continuous fibrinolytic coverage across a 24-hour period.

For travel-related DVT prevention, a specific protocol has been studied: 150 mg of nattokinase combined with pycnogenol — two tablets taken 2 hours before a flight and two tablets taken 6 hours after landing. This use-case protocol is distinct from daily cardiovascular supplementation and should not be assumed to carry over as a general dosing recommendation.

5. Delivery Format: Why Capsule Type Affects Results

How the nattokinase is delivered matters as much as the dose. Standard capsules — gelatin or plain veggie caps — release their contents into the stomach, where the acidic environment (pH 1–3) and pepsin can degrade a portion of the active enzyme before absorption. Nattokinase is stable in a pH range of 6.0–12.0, which corresponds to the environment of the small intestine, not the stomach. Integrative medicine clinical guidance recommends enteric-coated or delayed-release formulations to protect enzyme activity during gastric transit — and several of the clinical studies showing positive results specifically used protected capsule formats.

Enteric-coated capsules are coated with a material that resists dissolution in acidic conditions and dissolves only when it reaches the less acidic small intestine (pH 6–7.5). Delayed-release capsules such as DRcaps use a similar principle — the capsule shell is designed to hold its contents intact through the stomach and release them in the small intestine for absorption, without relying on traditional plasticizer-containing enteric coatings. The clinical implication is that 2,000 FU from a well-delivered, enzyme-protective capsule may provide more bioactive nattokinase than 2,000 FU from a standard capsule exposed to gastric acid. This is why FU activity at the point of manufacture must be paired with a delivery format that preserves it through digestion.

A useful practical check: if a supplement lists milligrams but not FU, or uses a standard capsule without any mention of acid protection, its label activity may not accurately represent what reaches your bloodstream. The combination of an adequate FU dose and an enzyme-protective delivery format is the complete picture for effective nattokinase supplementation.

6. Safety and Who Should Avoid Nattokinase

Nattokinase has a generally favorable safety record in clinical trials. Studies at standard doses (2,000–4,000 FU per day) lasting up to 8 weeks in healthy adults and those with mild-to-moderate cardiovascular risk have reported no significant liver toxicity, kidney toxicity, or serious adverse events. The most comprehensive assessment from the 2023 systematic review found that high-quality RCTs did not report serious adverse effects at the doses tested — though the authors acknowledged that long-term safety data at higher doses remains limited.

The primary safety concern is its blood-thinning effect. Because nattokinase enhances fibrinolysis and inhibits coagulation factors, it amplifies the effects of anticoagulant and antiplatelet medications. Memorial Sloan Kettering Cancer Center's integrative medicine database notes that nattokinase theoretically increases bleeding risk when used alongside warfarin, heparin, rivaroxaban (Xarelto), apixaban (Eliquis), aspirin, and clopidogrel (Plavix). Case reports in the medical literature have documented bleeding complications in patients combining nattokinase with anticoagulants without physician supervision — and at least one documented case of mechanical heart valve thrombosis after a patient independently substituted nattokinase for warfarin. Nattokinase is not a substitute for prescription anticoagulants.

The following populations should avoid nattokinase or consult a physician before use:

• Anyone taking prescription anticoagulants (warfarin, DOACs) or antiplatelet drugs (aspirin, clopidogrel)
• Individuals with bleeding disorders, hemophilia, or low platelet counts
• Those with a recent history of hemorrhagic stroke or active bleeding
• People scheduled for surgery within 2 weeks (stop at least 14 days before any procedure)
• Pregnant or nursing women (safety data is absent for these populations)
• Individuals with severe hepatic impairment

Health Canada has also flagged a nuance specific to purified supplements: raw natto food contains high levels of vitamin K2, which partially offsets nattokinase's blood-thinning effect. When nattokinase is isolated as a supplement and vitamin K2 is removed during processing, this natural offset disappears — theoretically increasing bleeding risk relative to consuming natto food directly. This is not a reason to avoid the supplement, but it underscores the importance of not combining it with other anticoagulants without medical supervision.

7. BioAbsorb Nattokinase Enzyme — Dosage You Can Count On

BioAbsorb Nutraceuticals formulates their Nattokinase Enzyme supplement with a focus on the delivery problem that undermines many nattokinase products. Each capsule contains 100 mg of nattokinase extract standardized to 2,000 FU of fibrinolytic activity — the dose used in the landmark randomized controlled trial for blood pressure and the threshold established for measurable fibrinolytic effects in single-dose pharmacokinetic research.

Where BioAbsorb differentiates is the capsule technology. Their nattokinase is delivered in DRcaps — a delayed-release veggie capsule that holds its contents intact through the acidic stomach environment and releases them in the small intestine, where nattokinase's optimal absorption pH of 6.0–12.0 is present. Unlike some enteric-coated products that use phthalate-containing coatings, DRcaps are free of phthalates and plasticizers. This matters for the practical question most supplement buyers face: will the dose on the label actually reach my bloodstream? With a delayed-release format, the answer is more reliably yes.

The BioAbsorb Nattokinase Enzyme supplement is non-GMO, contains no artificial additives, and is manufactured in a GMP-certified Canadian facility. It is available in a 60-capsule (60-day supply) and 180-capsule (6-month supply) format. The recommended dose is 1 capsule once daily on an empty stomach — consistent with the clinical dosing standard. For those considering a higher-dose protocol under physician supervision, the capsule format lends itself to the twice-daily approach used in some cardiovascular studies.

BioAbsorb's formulation philosophy is straightforward: use the dose the research supports, deliver it in a format that preserves enzyme activity, and avoid additives that compromise product integrity. For consumers who have researched nattokinase thoroughly enough to understand why FU and delivery format matter, BioAbsorb Nattokinase Enzyme is built to match those standards.

Frequently Asked Questions

Is 2,000 FU enough, or should I take more?

For general cardiovascular maintenance and mild blood pressure support, 2,000 FU per day is the best-evidenced starting point — it's the dose used in the key blood pressure RCT and the pharmacokinetic studies confirming oral bioavailability. If your goals extend to more active antithrombotic support or you are working with a cardiovascular risk factor under physician guidance, some protocols use 4,000 FU split across two daily doses. Doses above 4,000 FU have only been studied in limited observational research and should not be self-initiated without medical supervision.

Should I take nattokinase in the morning or at night?

No clinical study has established a clear advantage for morning versus evening dosing. The more important variable is fasted state — taking it at least 30–60 minutes before eating or 2 hours after a meal, regardless of time of day. Some practitioners prefer evening dosing on the logic that fibrinolytic activity covers the overnight window; others prefer morning for adherence. Consistency with your chosen schedule matters more than the specific hour.

Can I take nattokinase if I'm already on a blood thinner?

No — not without direct physician supervision. Nattokinase has documented fibrinolytic and anti-coagulation effects that amplify the action of drugs like warfarin, apixaban, rivaroxaban, aspirin, and clopidogrel. The combination can increase bleeding risk substantially. Case reports document both bleeding complications and at least one mechanical valve thrombosis when nattokinase was substituted for warfarin. This is one of the clearest contraindications in the nattokinase literature.

How long does it take for nattokinase to start working?

Measurable fibrinolytic effects begin within 2 hours of ingestion, according to the 2015 Scientific Reports single-dose study, which tracked D-dimer and Factor VIII levels over an 8-hour post-dose window. For clinical outcomes like blood pressure reduction, the randomized trial evidence shows meaningful changes over 6–8 weeks of daily use. Expect enzymatic activity within hours, but cardiovascular benefits measured in clinical endpoints typically require consistent daily use over at least 4–8 weeks.

Does taking nattokinase with food reduce its effectiveness?

Food can reduce nattokinase effectiveness because stomach acid and digestive proteases are elevated during active digestion, increasing the chance that the enzyme is degraded before reaching the small intestine. Taking it on an empty stomach minimizes this exposure. Delayed-release or enteric-coated formulations add a second layer of protection, but combining a protective capsule format with fasted-state dosing provides the most reliable enzyme delivery.

What is the difference between nattokinase and natto food?

Natto is the whole fermented soybean food from which nattokinase was first isolated. Natto contains nattokinase along with high concentrations of vitamin K2, which has its own cardiovascular properties but also partially moderates nattokinase's blood-thinning effects. Nattokinase supplements are the purified enzyme extracted from natto — typically with vitamin K2 removed. The supplement form allows precise dosing in FU and avoids natto's strong flavour and texture, which many people find difficult to consume regularly.

Conclusion

The clinical evidence for nattokinase dosing points to a clear framework: start at 2,000 FU daily on an empty stomach, in a delayed-release or enteric-coated capsule, and allow 6–8 weeks of consistent use before assessing cardiovascular outcomes. Higher doses are used in more aggressive protocols, but long-term safety data above 4,000 FU is still limited, and anyone with a cardiovascular condition or medication regimen should involve their physician before adjusting dose. For a formula built specifically around the delivery and dose the research supports, BioAbsorb Nattokinase Enzyme — 100 mg / 2,000 FU in DRcaps, GMP-certified, non-GMO — is designed to deliver exactly that.

Research References

1. Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial. Hypertension Research, Vol. 31 (2008). Randomized, double-blind, placebo-controlled trial in 86 participants; daily 2,000 FU nattokinase over 8 weeks produced a mean 5.55 mmHg reduction in systolic blood pressure compared to placebo.
2. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports, Vol. 5 (2015). Double-blind crossover study in 12 healthy males; a single 2,000 FU oral dose elevated D-dimer by ~44% at 6 hours and reduced Factor VIII activity — the first direct evidence that oral nattokinase is absorbed intact with measurable systemic fibrinolytic activity.
3. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, Vol. 24(8) (2023). Pooled analysis of 6 high-quality RCTs with 546 participants confirming statistically significant reductions in systolic and diastolic blood pressure (p < 0.00001), with mixed signals on lipid outcomes at lower doses.
4. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine, Vol. 9 (2022). Large observational study at 10,800 FU/day over 12 months; improvement rates of 66.5–95.4% in carotid artery plaque and lipid outcomes — authors note 3,600 FU/day was ineffective for these endpoints.
5. Research Progress of Nattokinase in Reducing Blood Lipid. Nutrients, Vol. 17(11) (2025). Comprehensive review of nattokinase dosing evidence establishing the 2,000–4,000 FU/day effective range for cardiovascular maintenance, and noting that doses up to 10,000 FU/day showed no serious side effects in short-term studies.
6. Nattokinase — Integrative Medicine Fact Sheet. University of Wisconsin Department of Family Medicine and Community Health. Summary of clinical dosing guidance, DVT travel protocol (150 mg + pycnogenol), and safety considerations for clinical use.
7. Nattokinase — Integrative Medicine Database. Memorial Sloan Kettering Cancer Center. Authoritative safety summary covering drug interactions with anticoagulants and antiplatelet agents, and noting the vitamin K2 offset mechanism relevant to supplemental vs. food-form nattokinase.
8. Nattokinase: Natural Product Information. Drugs.com / Natural Products Database. Documents Health Canada's safety position, the vitamin K2 removal consideration, case reports of valve thrombosis (warfarin substitution), and the theoretical bleeding risk mechanism with prescription anticoagulants.
9. Why Take Nattokinase on an Empty Stomach? Biology Insights. Reviews gastric enzyme dynamics and the rationale for fasted-state dosing, including the pH stability window of 6.0–12.0 and the role of delivery format in protecting enzyme activity through gastric transit.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.